Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial

医学 呼出气一氧化氮 布地奈德 福莫特罗 哮喘 吸入器 沙丁胺醇 布地奈德/福莫特罗 子群分析 内科学 支气管扩张剂 随机对照试验 恶化 临床试验 嗜酸性粒细胞 肺活量测定 置信区间
作者
Ian Pavord,Mark Holliday,Helen K. Reddel,Irene Braithwaite,Stefan Ebmeier,Robert J. Hancox,Tim Harrison,Claire Houghton,Karen Oldfield,Alberto Papi,Mathew Williams,Mark Weatherall,Richard Beasley,Andrew Corin,Colin Helm,Bhuwan Poudel,Davitt Sheahan,Pamela Sheahan,Miriam Bennett,Caterina Chang
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:8 (7): 671-680 被引量:96
标识
DOI:10.1016/s2213-2600(20)30053-9
摘要

Whether blood eosinophil counts and exhaled nitric oxide (FeNO) are associated with important outcomes in mild asthma is unclear. In this prespecified subgroup analysis of a previously published open-label clinical trial, we aimed to assess associations between blood eosinophil counts and FeNO with outcomes and response to asthma treatment.In the previously reported 52-week, open-label, randomised controlled trial, people with mild asthma receiving only β agonist reliever inhalers were enrolled at one of 16 clinical trials units in New Zealand, the UK, Italy, or Australia. Eligible participants were randomly assigned (1:1:1, stratified by country), to receive inhalers to take as-needed salbutamol (two inhalations of 100 μg in a pressurised metered dose inhaler), maintenance budesonide (200 μg twice per day by inhaler) plus as-needed salbutamol (two inhalations of 100 μg), or as-needed budesonide-formoterol (one inhalation of 200 μg budesonide and 6μg formoterol by inhaler). The primary outcome was the annual rates of asthma exacerbations per patient, and in this prespecified subgroup analysis, we assessed whether annual exacerbation rates in each treatment group were significantly different depending on levels of blood eosinophil count, FeNO, or a composite score of both. Analyses were done for patients with available biomarker measurements The study was registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12615000999538.675 participants were enrolled between March 17, 2016, and Aug 29, 2017, of whom 656 had results for blood eosinophil analysis and 668 had results for FeNO. Of the patients who received as-needed salbutamol, the proportion of patients having a severe exacerbation increased progressively with increasing blood eosinophil count (two [4%] of 49 participants with <0·15 × 109/L, six [6%] of 93 with 0·15 to <0·3 × 109/L, and 15 [19%] of 77 with ≥0·3 × 109/L; p=0·014). There were no significant interactions between blood eosinophil count or FeNO level and the effect of as-needed budesonide-formoterol compared with as-needed salbutamol for either exacerbations or severe exacerbations. However, there were significant interactions between blood eosinophil count subgroups and the effect of maintenance budesonide plus as-needed salbutamol compared with as-needed salbutamol, both for exacerbations (p=0·0006) and severe exacerbations (p=0·0007). Maintenance budesonide plus as-needed salbutamol was more effective than as-needed salbutamol in patients with blood eosinophil counts of 0·3 × 109/L or more, both for exacerbations (rate ratio 0·13 [95% CI 0·05-0·33]) and severe exacerbations (risk odds ratio 0·11 [0·03-0·45]). This difference was not seen for blood eosinophil counts of less than 0·15 × 109/L (1·15 [0·51-1·28] for exacerbations and 5·72 [0·97-33·60] for severe exacerbations). There was no consistent interaction between treatment response and FeNO or the composite score.In patients with mild asthma, the effects of as-needed budesonide-formoterol on exacerbations are independent of biomarker profile, whereas the benefits of maintenance inhaled budesonide are greater in patients with high blood eosinophil counts than in patients with low counts.AstraZeneca, Health Research Council of New Zealand.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
抹茶肥肠完成签到,获得积分10
3秒前
脑洞疼应助11采纳,获得10
3秒前
3秒前
5秒前
sheila完成签到,获得积分10
5秒前
5秒前
枫叶的虫子完成签到,获得积分10
6秒前
6秒前
Pooh发布了新的文献求助10
7秒前
7秒前
8秒前
深情安青应助莫非采纳,获得10
9秒前
向阳而生o完成签到,获得积分10
9秒前
xxx发布了新的文献求助10
9秒前
10秒前
llll发布了新的文献求助10
11秒前
yao发布了新的文献求助30
11秒前
12秒前
loski发布了新的文献求助10
12秒前
可爱的函函应助偷乐采纳,获得10
14秒前
清晾油完成签到,获得积分10
14秒前
15秒前
脑洞疼应助科研通管家采纳,获得10
15秒前
科目三应助科研通管家采纳,获得10
15秒前
坦率的匪应助科研通管家采纳,获得10
15秒前
科研通AI5应助科研通管家采纳,获得10
15秒前
JamesPei应助科研通管家采纳,获得10
15秒前
解语花应助科研通管家采纳,获得50
15秒前
czh应助科研通管家采纳,获得10
15秒前
JamesPei应助科研通管家采纳,获得10
15秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
bkagyin应助科研通管家采纳,获得10
15秒前
Hello应助科研通管家采纳,获得10
15秒前
坦率的匪应助科研通管家采纳,获得10
15秒前
ludov应助科研通管家采纳,获得10
15秒前
16秒前
搜集达人应助科研通管家采纳,获得10
16秒前
隐形曼青应助科研通管家采纳,获得10
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988838
求助须知:如何正确求助?哪些是违规求助? 3531250
关于积分的说明 11252914
捐赠科研通 3269838
什么是DOI,文献DOI怎么找? 1804820
邀请新用户注册赠送积分活动 881943
科研通“疑难数据库(出版商)”最低求助积分说明 809028